Onconetix Soars 13.69% on Ocuvex Merger Announcement

On July 16, 2025, Onconetix's stock surged by 13.69% in pre-market trading, marking a significant rise that caught the attention of investors and analysts alike.

Onconetix has announced a definitive merger agreement with Ocuvex Therapeutics, a privately-held company. Under the terms of the agreement, Onconetix will acquire all of the issued and outstanding equity interests of Ocuvex. This strategic move is expected to significantly dilute the existing Onconetix shareholders, who will retain only 10% of the issued and outstanding equity interests of the combined entity. The merger is structured as a stock-based transaction, with Ocuvex stockholders receiving shares of Onconetix common stock in exchange for their equity.

The merger agreement includes customary representations, warranties, and covenants, ensuring that both parties adhere to the terms and conditions set forth. The merger is subject to the satisfaction of customary closing conditions, including regulatory approvals and shareholder votes. The transaction is expected to close within the next few months, pending the fulfillment of these conditions.

Onconetix has also announced the election of Andrew Oakley as the Lead Independent Director. Oakley, an experienced pharmaceutical and biotech industry professional, brings a wealth of knowledge and expertise to the role. His appointment is expected to strengthen the company's governance and strategic direction as it navigates the merger and future growth opportunities.